X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PANACEA BIOTECH - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PANACEA BIOTECH AUROBINDO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 15.6 145.3 10.8% View Chart
P/BV x 4.0 3.2 124.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs895149 601.9%   
Low Rs62282 755.8%   
Sales per share (Unadj.) Rs254.684.1 302.6%  
Earnings per share (Unadj.) Rs39.3-18.3 -214.5%  
Cash flow per share (Unadj.) Rs46.6-6.7 -695.3%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.083.7 191.1%  
Shares outstanding (eoy) m585.8861.25 956.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.4 217.0%   
Avg P/E ratio x19.3-6.3 -306.1%  
P/CF ratio (eoy) x16.3-17.2 -94.5%  
Price / Book Value ratio x4.71.4 343.7%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3907,074 6,281.7%   
No. of employees `00014.02.8 508.4%   
Total wages/salary Rs m17,6781,449 1,219.8%   
Avg. sales/employee Rs Th10,667.81,874.1 569.2%   
Avg. wages/employee Rs Th1,264.3527.0 239.9%   
Avg. net profit/employee Rs Th1,645.8-407.7 -403.6%   
INCOME DATA
Net Sales Rs m149,1575,154 2,894.2%  
Other income Rs m1,159100 1,161.2%   
Total revenues Rs m150,3165,254 2,861.3%   
Gross profit Rs m34,343-766 -4,481.6%  
Depreciation Rs m4,276711 601.4%   
Interest Rs m6671,503 44.4%   
Profit before tax Rs m30,558-2,881 -1,060.9%   
Minority Interest Rs m5011 464.8%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m7,59717 45,217.3%   
Profit after tax Rs m23,012-1,121 -2,052.3%  
Gross profit margin %23.0-14.9 -154.9%  
Effective tax rate %24.9-0.6 -4,262.3%   
Net profit margin %15.4-21.8 -70.9%  
BALANCE SHEET DATA
Current assets Rs m92,0623,810 2,416.2%   
Current liabilities Rs m66,2238,365 791.6%   
Net working cap to sales %17.3-88.4 -19.6%  
Current ratio x1.40.5 305.2%  
Inventory Days Days106156 68.1%  
Debtors Days Days6867 100.7%  
Net fixed assets Rs m62,91914,480 434.5%   
Share capital Rs m58661 955.8%   
"Free" reserves Rs m93,133903 10,312.6%   
Net worth Rs m93,7195,127 1,827.9%   
Long term debt Rs m1,8145,832 31.1%   
Total assets Rs m162,49419,433 836.2%  
Interest coverage x46.8-0.9 -5,106.5%   
Debt to equity ratio x01.1 1.7%  
Sales to assets ratio x0.90.3 346.1%   
Return on assets %14.62.0 741.9%  
Return on equity %24.6-21.9 -112.3%  
Return on capital %32.73.6 900.3%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m75,8381,539 4,927.1%   
Fx outflow Rs m30,224942 3,208.5%   
Net fx Rs m45,613597 7,637.9%   
CASH FLOW
From Operations Rs m32,786599 5,471.6%  
From Investments Rs m-17,870-438 4,080.9%  
From Financial Activity Rs m-19,153-303 6,329.3%  
Net Cashflow Rs m-4,239-141 2,999.8%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.6 1,325.0%  
FIIs % 27.7 1.3 2,130.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.6 43.2%  
Shareholders   69,601 10,259 678.4%  
Pledged promoter(s) holding % 8.6 35.1 24.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS